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Abstract 
Purpose: To clarify the usefulness and safety of finasteride in the treatment of patients with benign 
prostatic hyperplasia (BPH) compared to placebo group or controls. 
Methods: In a meta-analysis, PubMed and Web of Science were searched to include relevant studies. 
The results were combined with a random effect model. Publication bias was evaluated using Egger 
regression asymmetry test. 
Results: Fourteen publications involving 17,364 patients were included in the study. Pooled results 
indicated that International Prostate Symptom Score (IPSS) in the finasteride group was lower 
[weighted mean difference (WMD) = -0.77, 95% CI= -0.97 to -0.57] compared to the placebo group. The 
usefulness of finasteride was higher in total prostate volume (TPV) [WMD= 0.13, 95%CI= 0.00 to 0.26] 
but lower in serum DHT [WMD= -1.18, 95%CI= -1.51 to -0.86] when compared to the placebo group. 
Drug-related adverse event was higher in the finasteride treatment group when compared to placebo 
group [summary RR= 1.95, 95%CI= 1.31-2.90]. 
Conclusion: Finasteride could improve the symptom score (IPSS and TPV) and reduce serum DHT. 
However, the potential adverse events, especially the drug-related adverse events in Finasteride 
treatment should be attention. 
 
Keywords: Benign prostatic hyperplasia, Finasteride, Meta-analysis 
 
This is an Open Access article that uses a funding model which does not charge readers or their institutions 
for access and distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative 
(http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and 
reproduction in any medium, provided the original work is properly credited. 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




In aging men, it is a common disease with benign 
prostatic hyperplasia (BPH). Urinary tract 
obstruction and even complete urinary retention 
often accompanied by prostate enlargement [1]. 
BPH can lead to bladder outlet obstruction 
(BOO), incomplete bladder emptying, poor 
stream and hesitancy. Therefore, it could affect a 
person’s quality of life [2,3]. In some more 
advanced situations, the risk with enlarged 
prostates (>30 mL) could increase three fold 
among men with acute urinary retention (AUR) 
[4]. 
 
Finasteride belongs to the competitive inhibitor of 
5a-reductase [5]. Application of this drug in a 
short period of time resulted in a decrease in 
serum dihydrotestosterone concentrations, a 
reduction in the prostate volume, and an 
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improvement in urinary flow rate [6,7]. While 
some studies [8-10] reported the effectiveness of 
finasteride in BPH, others did not find it better 
than the placebo or control [11]. Thus, the aim of 
this meta-analysis was to compare the outcomes 




Search criteria and inclusion criteria 
 
PubMed and Web of Knowledge databases were 
reached for records as at May 2015. The search 
utilized the terms ‘benign prostatic hypertrophy’, 
‘prostatic hyperplasia’, or ‘BPH’ in combination 
with ‘finasteride’ or ‘5ar inhibitor’. List of 
references from all full research and review 
articles retrieved were also used to identify other 
relevant articles. All the articles and abstracts 
were reviewed. 
 
Two investigators independently searched and 
reviewed articles for eligibility using the following 
inclusion criteria:: (1) written in English; (2) used 
randomized controlled trials (RCTs) design; (3) 
exposure of interest was the treatment using 
finasteride; (4) disease of interest was BPH, and 
(5) mean and standard deviation (SD) for 
International Prostate Symptom Score (IPSS), 
total prostate volume (TPV) (cm3), peak urinary 
flow (Qmax) (ml/s), serum testosterone (pg/ml) or 
dihydrotestosterone (DHT) (pg/ml) (or data to 
calculate them were provided) and the number of 





The following data independently extracted by 
two authors from studies included: first author’s 
last name, publication years, sample size, age, 
the methods of treatment, treatment duration, the 
mean and SD for continuous variables, the 
numbers of any AE, withdrawal due to AE, drug-





Dichotomous data were presented as odds ratios 
(OR) and 95% confidence interval (95% CI), and 
continuous parameters were shown as weighted 
mean difference (WMD) and 95% CI. Pooled 
treatment effect was determined with a random-
effects model, which considers between-study 
variation [12]. Heterogeneity was assessed by 
using I2 statistic [13]. Egger’s test was used to 
assess the publication bias [14]. A sensitivity 
analysis by exclusion of one study at the time 
was performed to assess the stability of results 
and potential sources of heterogeneity [15]. 
Meta-analysis was performed on STATA version 
10.0. The level of significance was defined as p-




Characteristics of included studies 
 
From the search, 487 publications from PubMed 
and 582 publications from Web of Knowledge 
were retrieved. A total of 1031 studies were 
excluded on review of each of the abstract or 
title. As shown in Figure 1, another 24 
publications were further excluded. Thus, 14 
publications [8-11, 16-25] (Table 1) covering 
17,364 patients were utilized for this report. 
When a clinical trial reported different outcomes, 
we then regarded them as a separate study. 
There were 11 articles that assessed the 
relationship between finasteride and placebo for 
BPH risk, 2 publications assessed the 
association between finasteride and dutasteride 





Figure 1: Study flow chart 
 
Efficacy of finasteride interventions 
 
There was only one study that reported the 
association for IPSS, and a significantly greater 
reduction in finasteride group than placebo group 
(WMD= -0.77, 95%CI= -0.97 to -0.57). The 
relation between finasteride group and placebo 
for BPH treatment was not significant in Qmax 
(WMD= -0.01, 95% CI= -0.14 to 0.11) (Figure 2).  
Four studies reported the association for 
finasteride treatment and TPV, and the 
association was significant in the treatment of 
finasteride group than placebo group (WMD= 
0.13,  95% CI  =  0.00 to 0.26)  (Figure  3).  The 




Figure 2: Forest plot and meta-analysis of the treatment for finasteride compared with placebo group with 
respect to Qmax 
 
 
Figure 3: Forest plot and meta-analysis of the treatment for finasteride compared with placebo group with 
respect to TPV 
 
treatment by finasteride showed a significant 
reduction association in serum DHT (WMD= -
1.18, 95%CI= -1.51 to -0.86) (Figure 4) and 
increase but not significant in serum testosterone 
(WMD= 0.19, 95%CI= -0.12 to 0.50) (Figure 5). 
 
In addition, the treatment effects between 
finasteride group and tamsulosin group showed 
that no significant association was found in the 
analyses for IPSS and Qmax. The treatment 
effects of finasteride were supported by a 
significant increase in serum DHT compared with 
dutasteride group (WMD= 1.49, 95%CI= 1.07 to 
1.91). 
 
Safety of finasteride interventions 
 
There are 6 studies conducted to assess the 
association of finasteride with AE. Pooled data 
indicated that there was no significant 
association in AE in treatment with finasteride 
than placebo (RR= 1.00, 95%CI= 0.94-1.07) 
(Figure 6). The association was not significant in 
withdrawal due to AE for the treatment with 
finasteride than placebo (RR= 0.98, 95%CI= 
0.85-1.14). Pooled data indicated drug-related 
AE were higher in finasteride group than that in 
placebo group (RR= 1.95, 95%CI= 1.31-2.90) 
(Figure 7). No significant association was found 
in the serious AE (RR= 0.91, 95%CI= 0.80-1.03) 




Figure 4: Forest plot and meta-analysis of the treatment for finasteride compared with placebo group with 
respect to serum DHT. 
 
 
Figure 5: Forest plot and meta-analysis of the treatment for finasteride compared with placebo group with 
respect to serum testosterone 
 
In addition, withdrawal from finasteride or 
tamsulosin was not associated with ADE, drug-
related adverse events. Similarly, ADE and 
withdrawal due to adverse events were not 
significantly associated with the treatment of 
finasteride compared with dutasteride group. 
 
Sensitivity analysis and publication bias 
 
A sensitivity analysis of the relationship between 
finasteride group and placebo group was 
conducted accordingly. However, no apparent 
effect was found on overall merged results. The 
potential publication bias assessed by Egger’s 
test (P= 0.176) showed no significant publication 
bias between finasteride group and placebo 




Findings from this study demonstrated that 
finasteride could improve the symptom score of 
IPSS and TPV. The treatment effect of 
finasteride had a reduction in serum DHT 
compared with placebo group. However, drug-
related AE reported higher in the finasteride 
group than in the placebo group. No significant 
associations were found in other three adverse 
events group. We also found a greater increased 
in serum DHT for the efficacy of finasteride than 
that in dutasteride group.  




Figure 6: The forest plot of BPH symptoms measured by AE about finasteride compared with placebo group. 
 
 
Figure 7: The forest plot of BPH symptoms measured by drug-related adverse events about finasteride 
compared with placebo group 
 
Several mechanisms have been proposed to 
explain the possible role of finasteride in the 
treatment of BPH. Finasteride belongs to 5-alpha 
reductase inhibitor (5-ARI), which is known to 
inhibit BPH-related disease progression by 
blocking 5-alpha reductase (5AR), which 
converts testosterone to DHT, a hormone 
responsible for prostate growth. Finasteride is a 
selective inhibitor of type II 5AR that could 
reduce the circulating DHT levels by about 70% 
[26]. The results in our study are similar to the 
previous meta-analysis of dutasteride treatment 
in urinary symptoms (IPSS and Qmax), TPV, and 
potential AE [27]. Like finasteride, dutasteride is 
a 5-ARI and may have the same effect as 
finasteride in the treatment of BPH. 
 
The major strength in this meta-analysis is the 
absence of any significant publication bias as 
demonstrated with the Egger’s test. However, the 
number of articles analysed are limited by our 
inclusion criteria. In addition, different doses of 
the drugs (finasteride: once daily (OD): 5 mg, 
Dutasteride: OD 0.5 mg, Tamsulosin: OD 0.4mg 
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or 0.2mg) were used in the studies that may lead 
to between-study heterogeneity. However, a 
random effect model was used in this report, 
which assumes that the individual specific effects 
are uncorrelated with the independent variables. 
Furthermore, the lack of information on the 
distribution of clinical and methodological 
variables can lead to potential sources of 
heterogeneity or inconsistency in each of the 




This study suggests that finasteride improves 
symptom score (IPSS and TPV) and reduce 
serum DHT in patients with BPH. However, 
potential AE, especially drug-related AE should 
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